Responses
Oncolytic and local immunotherapy
Original research
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.